Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Nanomedicine ; 12: 6677-6685, 2017.
Article in English | MEDLINE | ID: mdl-28932113

ABSTRACT

Metabolic reengineering using nanoparticle delivery represents an innovative therapeutic approach to normalizing the deregulation of cellular metabolism underlying many diseases, including cancer. Here, we demonstrated a unique and novel application to the treatment of malignancy using a short-chain fatty acid (SCFA)-encapsulated lipid-based delivery system - liposome-encapsulated acetate nanoparticles for cancer applications (LITA-CAN). We assessed chronic in vivo administration of our nanoparticle in three separate murine models of colorectal cancer. We demonstrated a substantial reduction in tumor growth in the xenograft model of colorectal cancer cell lines HT-29, HCT-116 p53+/+ and HCT-116 p53-/-. Nanoparticle-induced reductions in histone deacetylase gene expression indicated a potential mechanism for these anti-proliferative effects. Together, these results indicated that LITA-CAN could be used as an effective direct or adjunct therapy to treat malignant transformation in vivo.


Subject(s)
Acetates/administration & dosage , Antineoplastic Agents/administration & dosage , Lipids/chemistry , Nanoparticles/administration & dosage , Animals , Cations/chemistry , Colonic Neoplasms/drug therapy , Colonic Neoplasms/genetics , Colonic Neoplasms/pathology , HCT116 Cells , HT29 Cells , Histone Deacetylases/genetics , Humans , Liposomes/chemistry , Mice , Nanoparticles/chemistry , Xenograft Model Antitumor Assays
2.
J Control Release ; 149(2): 111-6, 2011 Jan 20.
Article in English | MEDLINE | ID: mdl-20888381

ABSTRACT

RNA interference (RNAi) is being widely explored as a means of tumour therapy due to the specific and potent silencing of targeted genes. However, in vivo delivery of RNAi effectors, such as small interfering RNA (siRNA) and detection of delivery is fraught with problems. Here, we describe novel theranostic PEGylated siRNA nanoparticles termed liposome-entrapped siRNA (LEsiRNA) nanoparticles. Our LEsiRNA nanoparticles are MR sensitive, contain labels for fluorescence microscopy/histology and promote functional siRNA delivery to tumours in mice leading to a significant reduction in both Survivin expression and tumour growth. LEsiRNA nanoparticles, administered by intravenous injection, were shown to accumulate in xenograft tumours by MR contrast image enhancements 24h post-administration. Fluorescence microscopy was used to corroborate the MR results and simultaneously demonstrate co-localisation of nanoparticles and siRNA within the tumours. The LEsiRNA nanoparticle-mediated delivery of the anti-cancer Survivin siRNA causes significant reduction in tumour growth when compared to controls. Our results suggest that LEsiRNA nanoparticles can be valuable as an in vivo delivery agent for siRNA therapy to tumours.


Subject(s)
Inhibitor of Apoptosis Proteins/genetics , Nanoparticles/chemistry , Neoplasms/therapy , RNA Interference , RNA, Small Interfering/administration & dosage , Repressor Proteins/genetics , Animals , Blotting, Western , Chemistry, Pharmaceutical , Contrast Media/administration & dosage , Drug Stability , Female , Fluorescent Dyes/administration & dosage , Liposomes , Magnetic Resonance Imaging , Mice , Mice, Inbred BALB C , Mice, Nude , Microscopy, Fluorescence , Neoplasms/diagnosis , Neoplasms/genetics , Neoplasms/pathology , Survivin
SELECTION OF CITATIONS
SEARCH DETAIL
...